Drug · Other
Peginterferon Alfa-2a
CI-DRUG-00000462Explore in graph →NCIt C33987 CHEMBL1201560 CIViC Approved
Regulatory
Approvals (14)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-24
- Retrieved
- Sep 28, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260928-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| US FDA | — | Efficacy supplement 2023-12-11 (see label) | approved | Dec 11, 2023 | openfda |
| US FDA | — | Efficacy supplement 2017-10-13 (see label) | approved | Oct 13, 2017 | openfda |
| US FDA | — | Efficacy supplement 2011-09-29 (see label) | approved | Sep 29, 2011 | openfda |
| US FDA | — | Efficacy supplement 2011-08-22 (see label) | approved | Aug 22, 2011 | openfda |
| US |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 3 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 0 | 0 | 7 | 18 | 14 | CA, US | Oct 16, 2002 | 2003-09 |
| Leukemia | Phase3 | Phase 3 | 0 | 0 | 3 | 3 | 0 | — | — | 2003-09 |
| Malignant Kidney Neoplasm | Phase3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2004-01 |
| Malignant Breast Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — |
Curated evidence
Clinical evidence (1)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26486786
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CALR EXON 9 FRAMESHIFT1 | ||||||||
| Peginterferon Alfa-2a | ||||||||
Clinical trials
Trials with this intervention (18)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05799612 | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT04798612 | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression(IPOS) | unknown |